Alivus Life Sciences Ltd

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has received an order from the Central Goods & Service Tax Department for FY 2020-21 and FY 2021-22, with an amount of Rs. 25,61,400, along with penalty and interest. The company will assess the impact and may appeal the order.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has acquired a 9.21% stake in Torrent Urja 19 Private Limited, a special purpose vehicle for setting up solar or other renewable energy projects, to comply with regulatory requirements for being a captive user under Indian electricity laws.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has incorporated a wholly owned subsidiary company in Brazil, Alivus Life Sciences Do Brasil Ltda., with an authorized capital of R$ 500,000.00 and 500,000 shares.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd held its 15th Annual General Meeting (AGM) on September 8, 2026, through video conferencing. The meeting was attended by 38 shareholders, and the requisite quorum was present. The Chairman highlighted the company's strong financial performance and future growth strategy. The Managing Director & CEO addressed the members on important milestones, FY26 performance, and the company's commitment to creating long-term value for shareholders and stakeholders.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd held its 15th Annual General Meeting (AGM) on September 8, 2026, through video conferencing. The meeting was attended by 38 shareholders, and the requisite quorum was present. The Chairman and Managing Director addressed the members, highlighting the company's strong financial performance, future growth strategy, and commitment to creating long-term value for shareholders and stakeholders.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has announced an investor meet to be held on September 10, 2026, and September 11, 2026, in Mumbai. The meet will be conducted in-person for various mutual funds and institutions.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has announced investor meet details under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has informed the stock exchanges about the details of Investors/Analyst meetings to be conducted on various dates in August and September 2026. The meetings will be held in virtual and in-person modes at various locations in Mumbai.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for a consideration of INR 91.2 million. The acquisition will enable Alivus to leverage its core portfolio selectively into advanced formulation development and expand its global customer base in the generic pharmaceutical segment.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has announced the acquisition of 76% stake in IQGEN-X Pharma Private Limited for INR 9.12 crores, subject to customary adjustments. The acquisition is expected to provide a wider spectrum for the company to offer a complete end-to-end solution to its customers in both API and CDMO space.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has announced an investors/analyst meeting on August 18-19, 2026, with various investment firms, including Green Lantern Capital, SIMPL, Burman Capital, and Karma Capital.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has announced the notice of its 15th Annual General Meeting (AGM) and e-voting information. The AGM will be held through video conferencing, and shareholders will be able to cast their votes on the proposed resolutions. The company has also confirmed the dispatch of the notice of AGM and the integrated annual report for the financial year 2025-26.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has submitted its Business Responsibility & Sustainability Report for FY 2025-26, as per SEBI regulations.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has submitted its Integrated Annual Report for FY 2025-26, as per Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report is available on the company's website and has been sent to shareholders through electronic mode.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has announced the notice of its 15th Annual General Meeting (AGM) for FY 2025-26, to be held on September 8, 2026. The meeting will be conducted through video conferencing or other audio-visual means. The company has also provided the facility for shareholders to exercise their right to vote on the resolutions proposed to be passed at the AGM by electronic means.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has announced an investor meet on August 12, 2026, to be attended by the company's representatives. The meeting will be held in Mumbai, and the schedule and mode may be subject to change due to exigencies.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd announces an investor/analyst meeting on August 12, 2026, in Mumbai, which may be subject to change due to exigencies.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd reported Q1 FY '27 results with revenue of INR640 crores, a 6.4% year-on-year growth, driven by strong non-GPL business growth of 26.5% year-on-year. The company expects healthy growth momentum in the non-GPL business to continue, supported by a robust product pipeline and sustained demand across all markets.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has announced a newspaper advertisement for its 15th Annual General Meeting (AGM) to be held on September 8, 2026, through video conferencing.

Alivus Life Sciences Ltd

Alivus Life Sciences Ltd has announced the record date for its 15th Annual General Meeting and declared a final dividend of Rs. 5.00 per equity share for the financial year ended March 31, 2026.